SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending as investors speculate on potential buyout targets like Sellas Life Sciences and Inhibrx to help the pharmaceutical giant navigate the upcoming patent cliff for its flagship cancer drug, Keytruda. The community is heavily focused on the competitive dynamics of oncology platform acquisitions and the high-stakes data readouts expected to shape future merger and acquisition activity in the sector.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is trending as investors debate its long-term potential, weighing concerns over recent price stagnation against the project's real-world revenue from physical merchandise and brand initiatives. Community members are actively discussing the token's value proposition relative to established meme coins, with many focusing on accumulation strategies despite market volatility.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending as investors react to a significant multi-year agreement with Apple to develop and supply custom ASIC silicon products through 2031, providing the company with long-term revenue visibility. Community discussions are highly focused on this deal as a major catalyst that reinforces Broadcom's central role in the AI infrastructure and semiconductor supply chain.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is currently facing volatility as investors weigh escalating geopolitical tensions in the Strait of Hormuz against ongoing corporate earnings reports and institutional market manipulation. Community discussions are split between those betting on a short-term dip due to energy risks and those anticipating a swift recovery driven by recurring peace deal narratives and institutional buying.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is facing intense volatility following the discovery of a critical privacy-related bug, sparking widespread community debate over supply integrity and the long-term viability of hidden-ledger assets. While some traders view the price dip as a strategic entry point and a validation of the protocol's improved security, others are liquidating positions, citing broken trust and the inability to verify if the vulnerability was exploited.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

The Russell 2000 ETF is currently experiencing heightened volatility and intense debate as traders weigh potential small-cap rotation against broader macro risks like interest rate uncertainty and geopolitical tensions. While some investors are banking on a bullish breakout fueled by index reshuffling and broadening leadership, others are actively hedging or betting on a downturn, citing elevated leverage and the historical tendency for small caps to struggle in high-rate environments.

Direxion Shares ETF Trust - Direxion Daily TSLA Bull 2X ETF

Direxion Daily TSLA Bull 2X Shares

TSLL is drawing heavy investor attention as community members debate the impact of Tesla's volatile price action, leveraged decay, and ongoing speculation surrounding a potential SpaceX partnership or merger. While some traders are aggressively buying the dip on technical setups, others are wary of the risks associated with leveraged ETFs and the complex derivatives market driving the underlying stock's movement.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is experiencing significant social sentiment and institutional interest, driven by anticipation surrounding the REGAL trial's final survival events and persistent buyout rumors involving major pharmaceutical players. Investors are actively debating the timing of topline data, the impact of potential institutional accumulation, and the stock's valuation as they wait for conclusive trial results.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending due to renewed geopolitical instability in the Middle East, specifically reports of Iranian aggression in the Strait of Hormuz and a subsequent U.S. crackdown on Iranian oil export licenses. Market participants are actively debating whether these tensions signify a return to sustained military conflict or if the price volatility is a temporary response to headline-driven news and ongoing market manipulation.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and social media users react to a flurry of updates regarding high-profile political figures and escalating geopolitical tensions in the Strait of Hormuz. Community discussion is heavily polarized, featuring intense debate over the impact of these international conflicts on the company's valuation and the broader political landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet...

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

4 Biotech Stocks Investors Should Watch in 2026

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector. 

Stoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Stoke Therapeutics (STOK) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business Updates

Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business Updates...

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?

STOK rides high as zorevunersen advances in late-stage Dravet syndrome studies and heads toward FDA filing plans.

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...

Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates

Stoke Therapeutics (STOK) delivered earnings and revenue surprises of +0.94% and +18.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Stoke Therapeutics Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

STOKStoke Therapeutics Inc

Fundamentals

Latest STOK News